Literature DB >> 22687849

Response to low-dose bortezomib in plasma cell leukemia patients with malignant pleural effusion and ascites: a case report and a review of the literature.

Yasunobu Sekiguchi1, Syuichi Shirane, Hidenori Imai, Keiji Sugimoto, Mutsumi Wakabayashi, Tomonori Sawada, Noriko Chigira, Kunimoto Ichikawa, Norio Komatsu, Masaaki Noguchi.   

Abstract

Pleural effusion or ascites complicating plasmacytoma is rare and has a poor prognosis. A 70-year-old man was diagnosed as plasma cell leukemia and one course of ranimustine-vindesine, melphalan, and prednisolone followed by melphalan and prednisone (MP) maintained a very good partial response. After MP he was diagnosed to have pleural effusion and ascites as a complication of the plasmacytoma. Low-dose bortezomib caused disappearance of the malignant effusion. The malignant effusions recurred after the end of the second course of bortezomib. High-dose dexamethasone vincristine, doxorubicin, cyclophosphamide, and prednisone yielded no benefit, the patient died of Aspergillus pneumonia.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22687849     DOI: 10.2169/internalmedicine.51.7061

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  3 in total

Review 1.  Advances in the treatment of extramedullary disease in multiple myeloma.

Authors:  Yating Li; Zhengxu Sun; Xiaoyan Qu
Journal:  Transl Oncol       Date:  2022-06-06       Impact factor: 4.803

2.  IgG Lambda Myeloma Presenting as Plasmacytic Ascites: Case Report and Review of Literature.

Authors:  Subhashis Mitra; Sanghamitra Mukherjee; Hema Chakraborty; Maitreyee Bhattacharyya
Journal:  Indian J Hematol Blood Transfus       Date:  2014-09-03       Impact factor: 0.900

3.  Myelomatous ascites and pleural effusion in relapsed multiple myeloma.

Authors:  Mizba Baksh; Ke Li; Liuyan Jiang; Victoria Alegria; Taimur Sher; Vivek Roy; Asher Chanan-Khan; Sikander Ailawadhi; Ricardo D Parrondo; Muhamad Alhaj Moustafa
Journal:  Clin Case Rep       Date:  2022-02-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.